COLUMBIA, Md., Oct. 30, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the “Company”), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today provided an update regarding the status of the audits of its 2015 and 2016 financial statements. The Company continues to work diligently to complete the audits and to regain compliance with its SEC reporting requirements as soon as practicable.